B2/C in 56.6% with mean lesion length by QCA of 24.1 mm with a mean RVD of 2.6 mm and a mean lumen obstruction of 66.1%. Pre-dilatation was performed in 94% and post-dilatation in 59%. The mean scaffold length was 27.4 mm with 36% of cases using !2 stents and 26% of cases using overlapping scaffolds. OCT or IVUS was used in 30%. Device success was 98.0% (failure to expand in 1 pts. and deliver in 5 pts.). Over the entire follow-up period, death occurred in 1.7% (5/297), myocardial infarction (MI) in 2.7% (total of 8 cases, 1 of peri-procedural), target lesion revascularization in 3.4%, target vessel revascularization (TVR) in 4.7%, non-target vessel revascularization 1.3%. Definite stent thrombosis (ST) occurred in 6 pts. (2.0%) and probable ST in 1 pt. (0.3%); all ST were early including one acute ST except of two case of definite ST which occurred at days 40 and 84, respectively. Overall MACE (death, MI, TVR) rate was 6.4% (19/297).
CONCLUSIONS This registry including patients with ACS and complex lesion characteristics documents a good safety and efficacy profile of the BVS. However, stent thrombosis rates in particular early after BVS implantation have to be closely monitored. More data including complex patient and lesion subsets as well as longer followups are needed to define the role of BVS in daily practice. BACKGROUND Tissue formation at coronary bifurcations is related to vascular endothelial shear stress, and postmortem pathological studies have described different patterns of neointimal coverage between the outer wall and inner wall at coronary bifurcations treated with first-generation drug-eluting stents (DES). Current everolimuseluting bioresorbable scaffolds (BRS) have thicker struts compared to their metallic counterparts, and could therefore have a stronger influence on vascular endothelial shear stress compared to DES. However, the neointimal coverage of bifurcation lesions treated with BRS has not been adequately studied. In the current study, we sought to evaluate the vascular response to BRS struts deployed at bifurcation segments using optical coherence tomography (OCT).
METHODS This study included 37 patients (51 bifurcation lesions) examined with coronary angiography including OCT 11.0 AE 2.1 months after BRS implantation. Cross-sectional area (CSA) of the bifurcation lesion with a side branch more than 1mm using OCT were analyzed every 200mm. All images were divided into 3 regions according to the shear stress: one half of the circumference of the vessel opposite to the ostium (OO), the side branch ostium (SO), and the vessel wall adjacent to the ostium (AO). All struts in OO, AO, and SO regions were classified as covered or uncovered. The thickness of coverage was measured in each CSA, and the averaged neointimal thickness (NIT) was calculated. Additionally, to evaluate the impact of the side branch size on neointimal proliferation, we classified side branches according to the ratio of the diameter of the side branch ostium (Ds) to the diameter of main branch (Dm).
RESULTS
The mean age of the study population was 57AE11 years. Mean BRS diameter and length were 3.1AE0.37 and 21.0AE5.7mm, respectively. The mean diameter of all side branches was 1.59AE0.55mm. Overall, there was a significant difference in NIT among the 3 examined regions (OO, 119AE68 vs. AO, 94AE35 vs. SO, 80AE41mm, p¼0.03). In addition, a significant difference was observed in the percentage of uncovered struts among the 3 regions (OO, 0.43 vs. AO, 1.4 vs. SO, 4.8%, p¼0.02). Lesions were divided into 2 groups based on a median value of Ds/Dm of 0.318 (large ratio side branch group ¼ LRSB, n¼26; and small ratio side branch group ¼ SRSB, n¼25). In the LRSB group, there was a significant difference in NIT (OO, 128AE61 vs. BACKGROUND Degradation of bioresorbable stents (BRS) has been shown to allow restoration of the treated segment's plasticity and reactivity to those resembling a non-stented artery, a desirable feature unattainable with metallic stents (BMS). We have previously reported the dynamic changes in arterial geometry in response to a novel nondrug eluting BRS as compared to BMS up to 2 years. This study provides an insight over a 3-year duration.
METHODS Forty-seven coronary arteries of 19 swine received BRS (Amaranth Medical, Mountain View, CA n¼34) or BMS (Liberte Ò Boston Scientific, Natick, MA n¼13). Optical coherence tomography (OCT) was done at day 0, 1 month (BRS, n¼26; BMS, n¼13), 1 year (BRS, n¼12; BMS, n¼4), 2 years (BRS, n¼13; BMS, n¼4) and 3 years post implant (BRS, n¼11; BMS, n¼3).
The lumen areas of reference segments increased over time in both BMS-caged segments (Day 0¼6.09AE1.80mm2, 2 Years¼10.55AE 2.95mm2 and 3 Years¼13.58AE3.23mm2, p<0.05) and the BAS-treated arteries (Day 0¼6.63AE1.21mm2, 2 Years¼11.63AE2.30mm2 and 3 Years¼12.16AE2.72mm2, p<0.05). BMS showed lumen area loss at 1 month as expected due to neointimal formation, and then minimal lumen area variance over time up to 3 years (Day 0¼6.79AE1.7mm2, 2 Years¼6.78AE2.25mm2, and 3 years¼7.37AE1.83mm2, p>0.05). In contrast, in BAS the early lumen area loss present at 1 month inverted into lumen gain that corresponded with the scaffold expansion as it degraded, paralleling the artery growth (scaffold area, Day 0¼6.87AE1.17mm2, 2 Years¼11.66AE1.51mm2, and 3 years¼13.87AE2.75 mm2, p<0.05) and allowing the treated segment to remodel (lumen area, Day 0¼6.87AE1.17mm2, 2 Years¼9.67AE1.56mm2, and 3 years¼11.94AE2.77mm2, p<0.05, Figure) . % Area Stenosis did not show significant difference between BMS and BRS over time.
CONCLUSIONS Between 2 and 3 years after implantation, BRS treated coronary artery segments continue to positively remodel, with further late lumen area gain paralleling the reference segment expansion over time. This pattern, uniquely possible due to scaffold degradation and unattainable in the BMS-caged segments, appears to be a reproducible and inherent behavior of non-drug eluting bioresorbable stents in the normal porcine coronary model.
